# Adze Biotechnology

Source: https://onco.cc/companies/adze-biotechnology/  
OnCo record `adze-biotechnology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adze Biotechnology is developing viruses engineered to infect and kill cancer cells while carrying immune-boosting drugs into the tumour. Its first product, Adze1.C, is in an early trial in melanoma that has spread.

## Summary

Adze Biotechnology Inc., based in Coral Gables, Florida, with an Australian subsidiary that sponsors its trial, develops oncolytic immunotherapies built on a recombinant adenovirus backbone that it says can be given systemically or injected into tumours and can carry checkpoint-inhibitor payloads. Sidney Hopps is chief executive and co-founder, and Paola Grandi, formerly chief scientific officer of CG Oncology, joined in June 2025 to lead preclinical and translational research. The company lists melanoma, hepatocellular carcinoma and triple-negative breast cancer as lead indications and announced a clinical collaboration with King's College London in breast cancer. Its first registered cancer trial, NCT07086105, a phase 1 dose-escalation study of intratumoural Adze1.C in metastatic melanoma at Australian sites, was posted on ClinicalTrials.gov in July 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Adze Biotechnology Inc; Adze Biotechnology Australia Pty Ltd; ADZE
- HQ: Coral Gables, FL
- Type: biotech
- Website: https://adzebiotech.com/

## Notes

- Founding year and financing not stated on the pages read. The US patent allowance for recombinant adenovirus claims (April 2024) is from the company news page. Read on 29 October 2026.

## Sources

- Official website: https://adzebiotech.com/
- News: https://adzebiotech.com/news/
- ClinicalTrials.gov: phase 1 trial of Adze1.C in melanoma (NCT07086105): https://clinicaltrials.gov/study/NCT07086105

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Melanoma](https://onco.cc/cancers/melanoma/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/)

---
JSON: https://onco.cc/api/v1/entities/adze-biotechnology.json